Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524962 · ClinicalTrials.gov registry record · Phase 1
Study of Descartes-30 in Acute Respiratory Distress Syndrome
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04524962 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT04524962, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
Interventions
- BIOLOGICAL Descartes 30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2023-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524962
The ClinicalTrials.gov registry entry for NCT04524962 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Descartes 30 is the first listed.
NCT04524962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524962 about?
NCT04524962 is a clinical study titled "Study of Descartes-30 in Acute Respiratory Distress Syndrome". Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
What is the current status of trial NCT04524962?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-02-23. Estimated completion is 2023-09-09.
What interventions are being tested in trial NCT04524962?
The interventions under investigation include: Descartes 30 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04524962?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.